Samir E. Witta

3.3k total citations
30 papers, 1.4k citations indexed

About

Samir E. Witta is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Samir E. Witta has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 16 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in Samir E. Witta's work include Lung Cancer Treatments and Mutations (15 papers), Histone Deacetylase Inhibitors Research (11 papers) and Colorectal Cancer Treatments and Studies (6 papers). Samir E. Witta is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Histone Deacetylase Inhibitors Research (11 papers) and Colorectal Cancer Treatments and Studies (6 papers). Samir E. Witta collaborates with scholars based in United States, Poland and Canada. Samir E. Witta's co-authors include Paul A. Bunn, Fred R. Hirsch, Rafał Dziadziuszko, Wilbur A. Franklin, Marileila Varella‐Garcia, Fred R. Hirsch, Michio Sugita, Christopher D. Coldren, Chan Zeng and Barbara A. Helfrich and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Samir E. Witta

29 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samir E. Witta United States 17 881 636 528 218 97 30 1.4k
Dean B. Reardon United States 18 791 0.9× 595 0.9× 315 0.6× 232 1.1× 99 1.0× 23 1.4k
Marion Wiesmann Switzerland 12 980 1.1× 477 0.8× 353 0.7× 166 0.8× 95 1.0× 20 1.6k
Valentina Pirazzoli United States 10 783 0.9× 566 0.9× 639 1.2× 252 1.2× 118 1.2× 13 1.4k
Maria Pinzon-Ortiz United States 8 599 0.7× 443 0.7× 326 0.6× 148 0.7× 55 0.6× 18 1.2k
Alice Loo United States 16 1.2k 1.3× 642 1.0× 384 0.7× 252 1.2× 157 1.6× 19 2.0k
Maria Sundvall Finland 20 1.2k 1.3× 949 1.5× 303 0.6× 289 1.3× 120 1.2× 33 1.8k
Adriana Estrada‐Bernal United States 16 604 0.7× 439 0.7× 467 0.9× 244 1.1× 108 1.1× 30 1.1k
Roseann Mulloy United States 8 583 0.7× 500 0.8× 409 0.8× 174 0.8× 71 0.7× 8 950
Joseph L.‐K. Chan United States 18 1.0k 1.2× 555 0.9× 139 0.3× 241 1.1× 112 1.2× 23 1.4k
Janni Mirosevich United States 12 866 1.0× 342 0.5× 626 1.2× 236 1.1× 89 0.9× 18 1.4k

Countries citing papers authored by Samir E. Witta

Since Specialization
Citations

This map shows the geographic impact of Samir E. Witta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samir E. Witta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samir E. Witta more than expected).

Fields of papers citing papers by Samir E. Witta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samir E. Witta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samir E. Witta. The network helps show where Samir E. Witta may publish in the future.

Co-authorship network of co-authors of Samir E. Witta

This figure shows the co-authorship network connecting the top 25 collaborators of Samir E. Witta. A scholar is included among the top collaborators of Samir E. Witta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samir E. Witta. Samir E. Witta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baumgartner, Laura, Samir E. Witta, & Jérôme Noailly. (2025). Parallel Networks to Predict TIMP and Protease Cell Activity of Nucleus Pulposus Cells Exposed and Not Exposed to Pro‐Inflammatory Cytokines. JOR Spine. 8(1). e70051–e70051. 1 indexed citations
2.
Witta, Samir E.. (2012). Histone Deacetylase Inhibitors in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(12). S404–S406. 10 indexed citations
3.
Witta, Samir E., Dan Chan, Luc Girard, et al.. (2012). Effects of entinostat onresistance to cetuximab and EGFR TKIs in non-small cell lung cancer.. Journal of Clinical Oncology. 30(15_suppl). e18077–e18077. 2 indexed citations
4.
Voi, Maurizio, John Nemunaitis, Jessica R. Bauman, et al.. (2012). 590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer. European Journal of Cancer. 48. 181–181. 5 indexed citations
5.
Witta, Samir E., Robert M. Jotte, Marcus A. Neubauer, et al.. (2012). Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy. Journal of Clinical Oncology. 30(18). 2248–2255. 156 indexed citations
6.
Witta, Samir E.. (2010). Supportive Care. Journal of Thoracic Oncology. 5(12). S472–S473. 1 indexed citations
7.
Witta, Samir E., Kimihide Yoshida, Barbara Frederick, et al.. (2009). Synergistic effect of SNDX-275 with lapatinib or erlotinib in breast, lung, or head and neck cancer cell lines expressing HER- 2. Journal of Clinical Oncology. 27(15_suppl). e14566–e14566. 1 indexed citations
8.
Dziadziuszko, Rafał, Daniel T. Merrick, Samir E. Witta, et al.. (2009). Insulin-like growth factor receptor 1 (IGF1R) protein expression, mRNA expression and gene copy number in operable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 7524–7524. 4 indexed citations
9.
Coldren, Christopher D., Barbara A. Helfrich, Samir E. Witta, et al.. (2006). Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines. Molecular Cancer Research. 4(8). 521–528. 107 indexed citations
10.
Bunn, Paul A., Rafał Dziadziuszko, Marileila Varella‐Garcia, et al.. (2006). Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Clinical Cancer Research. 12(12). 3652–3656. 46 indexed citations
11.
Basche, M., Daniel L. Gustafson, Scott N. Holden, et al.. (2006). A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12(18). 5471–5480. 77 indexed citations
12.
Hirsch, F. R., Wilbur A. Franklin, J. McCoy, et al.. (2006). Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. Journal of Clinical Oncology. 24(18_suppl). 7072–7072. 19 indexed citations
13.
Witta, Samir E., Robert M. Gemmill, Fred R. Hirsch, et al.. (2006). Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines. Cancer Research. 66(2). 944–950. 420 indexed citations
14.
Álvarez, Enrique, Wenbo Zhou, Samir E. Witta, & Curt R. Freed. (2005). Characterization of the Bex gene family in humans, mice, and rats. Gene. 357(1). 18–28. 60 indexed citations
15.
Hirsch, Fred R. & Samir E. Witta. (2005). Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Current Opinion in Oncology. 17(2). 118–122. 57 indexed citations
16.
Hirsch, Fred R., Wilbur A. Franklin, Samir E. Witta, et al.. (2004). Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays. Journal of Clinical Oncology. 22(14_suppl). 7027–7027. 5 indexed citations
17.
Gore, Lia, Scott N. Holden, M. Basche, et al.. (2004). Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3026–3026. 17 indexed citations
18.
Zawada, W. Michael, Edward D. Clarkson, Paul J. Golueke, et al.. (1998). Somatic cell cloned transgenic bovine neurons for transplantation in parkinsonian rats. Nature Medicine. 4(5). 569–574. 49 indexed citations
19.
Witta, Samir E. & Sheryl M. Sato. (1997). XlPOU 2 is a potential regulator of Spemann’s Organizer. Development. 124(6). 1179–1189. 17 indexed citations
20.
Witta, Samir E., Veena R. Agarwal, & Sheryl M. Sato. (1995). XlPOU 2, a noggin-inducible gene, has direct neuralizing activity. Development. 121(3). 721–730. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dean B. Reardon Breakdown of academic impact, for papers by Marion Wiesmann Breakdown of academic impact, for papers by Valentina Pirazzoli Breakdown of academic impact, for papers by Maria Pinzon-Ortiz Breakdown of academic impact, for papers by Alice Loo Breakdown of academic impact, for papers by Maria Sundvall Breakdown of academic impact, for papers by Adriana Estrada‐Bernal Breakdown of academic impact, for papers by Roseann Mulloy Breakdown of academic impact, for papers by Joseph L.‐K. Chan Breakdown of academic impact, for papers by Janni Mirosevich
Rankless by CCL
2026